DNA Therapeutics is at the forefront of medical approaches to DNA repair Induced cancer resistance to therapies. It develops 1^st-in-class targeted therapeutics addressing the fact that radiotherapy and chemotherapy often fail in the treatment of advanced cancers, due to tumor’s enhanced capacity to repair DNA lesions caused by the DNA damaging treatments that are radiotherapy and chemotherapy. It develops its original siDNA (signal interfering DNA) technology platform and innovative targeting drugs by interfering with DNA damage repair pathways - proven targets in cancer therapies.

The 1^st siDNA-based molecule, Dbait, is a mimic of DNA double strand break (DSB) to divert and disorganize the repair system responsible of recognizing and fixing DNA DSBs in cells. The aim of Dbait is to compromise the ability of cancer cells to repair the DSBs caused by conventional cancer therapies, thus to address these unmet needs.

Preclinical proofs of concept of Dbait have been achieved in various animal models by local administration in association with radiotherapy  and in spontaneous intestinal tumors in genetically engineered mice by oral administration in associated with chemotherapy. Biomarkers of Dbait's bioactivity have been identified and under development.

DRIIM, the 1^st-in-human trial of DT01 (a cholesterol-Dbait conjugate) combines with radiotherapy in melanoma-in-transit patients has been initiated in Q4 2011 in France. As local melanoma metastases, the presence of multiple tumor nodules in which some are treated by DT01 and irradiation, others only irradiated, provides the opportunity to evaluate not only the safety and tolerance, but also the clinical proof of concept of DT01 with a limited number of patients at this early stage of clinical development.

DNA Therapeutics believes that Dbait opens the era of supra-molecular therapy (protein complex pathway targeting).

=> For more details, please check our flyer or fact sheet